Financial Information Table Of Contents Page Unaudited Us Gaap Consolidated Balance Sheets 15 Unaudited Us Gaap Consolidated Statements Of Income 16 Unaudited Us Gaap Consolidated Statements Of Cash Flows 17 Selected Notes To The Unaudited Us Gaap Financial Statements (1) Earnings Per Share (eps) 20 (2) Analysis Of Revenues 21 Non Gaap Reconciliation 22 Unaudited Us Gaap Consolidated Balance Sheets (in Millions, Except Par Value Of Shares) June 30, 2016 December 31, 2015 Assets Current Assets: Cash And Cash Equivalents $ 693.4 $ 135.5 Restricted Cash 20.0 86.0 Accounts Receivable, Net 2,412.4 1,201.2 Inventories 5,798.7 635.4 Prepaid Expenses And Other Current Assets 733.6 197.4 Total Current Assets 9,658.1 2,255.5 Non-current Assets: Investments 174.0 50.8 Property, Plant And Equipment (pp&e), Net 6,596.3 828.1 Goodwill 12,962.4 4,147.8 Other Intangible Assets, Net 40,890.3 9,173.3 Deferred Tax Asset 129.6 121.0 Other Non-current Assets 309.8 33.3 Total Assets 70,720.5 16,609.8 Liabilities And Equity Current Liabilities: Accounts Payable And Accrued Expenses 3,728.1 2,050.6 Short Term Borrowings 2,715.2 1,511.5 Other Current Liabilities 411.5 144.0 Total Current Liabilities 6,854.8 3,706.1 Non-current Liabilities: Long Term Borrowings 21,312.1 69.9 Deferred Tax Liability 10,053.8 2,205.9 Other Non-current Liabilities 2,736.8 798.8 Total Liabilities 40,957.5 6,780.7 Equity: Common Stock Of 5p Par Value; 1,000 Shares Authorized; And 906.9 Shares Issued And Outstanding (2015: 1,000 Shares Authorized; And 601.1 Shares Issued And Outstanding) 81.0 58.9 Additional Paid-in Capital 24,473.2 4,486.3 Treasury Stock: 9.1 Shares (2015:9.7 Shares) (302.3) (320.6) Accumulated Other Comprehensive Loss (385.8) (183.8) Retained Earnings 5,896.9 5,788.3 Total Equity 29,763.0 9,829.1 Total Liabilities And Equity $ 70,720.5 $ 16,609.8 Unaudited Us Gaap Consolidated Statements Of Income (in Millions) 3 Months Ended June 30, 6 Months Ended June 30, 2016 2015 2016 2015 Revenues: Product Sales $ 2,322.1 $ 1,476.2 $ 3,949.4 $ 2,899.4 Royalties & Other Revenues 107.0 81.4 189.0 146.6 Total Revenues 2,429.1 1,557.6 4,138.4 3,046.0 Costs And Expenses: Cost Of Sales 778.1 228.0 1,026.7 455.8 Research And Development 294.8 775.9 511.9 969.6 Selling, General And Administrative(1) 675.3 496.0 1,150.2 914.3 Integration And Acquisition Costs 363.0 (212.4) 454.1 (136.7) Amortization Of Acquired Intangible Assets 213.0 131.3 347.6 219.6 Reorganization Costs 11.0 13.3 14.3 28.5 Gain On Sale Of Product Rights (2.3) (7.1) (6.5) (12.3) Total Operating Expenses 2,332.9 1,425.0 3,498.3 2,438.8 Operating Income From Continuing Operations 96.2 132.6 640.1 607.2 Interest Income 1.6 0.6 2.6 2.6 Interest Expense (87.2) (11.3) (131.9) (20.9) Other Income/(expense), Net 6.0 (2.0) (2.5) 2.3 Total Other Expense, Net (79.6) (12.7) (131.8) (16.0) Income From Continuing Operations Before Income Taxes And Equity In (losses)/earnings Of Equity Method Investees 16.6 119.9 508.3 591.2 Income Tax Benefit/(charge) 70.9 44.1 (11.2) (13.3) Equity In (losses)/earnings Of Equity Method Investees, Net Of Taxes (0.9) 0.1 (1.0) (0.9) Income From Continuing Operations, Net Of Taxes 86.6 164.1 496.1 577.0 Loss From Discontinued Operations, Net Of Taxes (248.7) (4.5) (239.2) (7.0) Net (loss)/income $ (162.1) $ 159.6 $ 256.9 $ 570.0 (1) Reported Sg&a For Periods Prior To June 30, 2016 Have Been Recast To Exclude Amortization Of Acquired Intangible Assets, Which Is Now Presented As A Separate Line Item.

Non GAAP Other expense, net increased $37 million, primarily due to higher interest expense as noted above. Taxation Effective Effective (in millions) tax rate tax rate Q2 2016 Q2 2015 Income tax benefit (US GAAP) $ 70.9 (427%) $ 44.1 (37%) Tax effect of adjustments (215.8) (121.5) Non GAAP Income tax charge $ (144.9) 16% $ (77.4) 13% The effective tax rate on US GAAP income in Q2 2016 was -427% (Q2 2015: -37%) and on a Non GAAP basis was 16% (Q2 2015: 13%). The effective tax rate in Q2 2016 on US GAAP income from continuing operations of -427% is negative, primarily due to the combined impact of the relative quantum of the profit before tax for the period by jurisdiction and the reversal of deferred tax liabilities from the Baxalta acquisition, including in higher tax territories, inventory and intangible assets amortization as well as significant acquisition and integration costs. The Q2 2015 US GAAP tax rate was negative primarily due to the reduction in deferred tax liabilities in relation to the impairment of IPR&D intangible assets, the re-measurement of uncertain tax positions relating to ongoing tax audits and the release of certain valuation allowances all recognized during Q2 2015. The effective tax rate in Q2 2016 on Non GAAP income from continuing operations is higher than the same period in 2015, primarily due to the benefit of the re-measurement of uncertain tax positions relating to ongoing tax audits and the release of certain valuation allowances in Q2 2015, which were not repeated in Q2 2016. Discontinued operations The loss from discontinued operations in Q2 2016 was $249 million, net of tax benefit of $101 million (Q2 2015: $5 million, net of tax) primarily related to a proposed legal settlement to resolve the previously disclosed Department of Justice investigation associated with the divested Dermagraft business. no dataFINANCIAL INFORMATION TABLE OF CONTENTS Page Unaudited US GAAP Consolidated Balance Sheets 15 Unaudited US GAAP Consolidated Statements of Income 16 Unaudited US GAAP Consolidated Statements of Cash Flows 17 Selected Notes to the Unaudited US GAAP Financial Statements (1) Earnings per share (“EPS”) 20 (2) Analysis of revenues 21 Non GAAP reconciliation 22 Unaudited US GAAP Consolidated Balance Sheets (in millions, except par value of shares) June 30, 2016 December 31, 2015 ASSETS Current assets: Cash and cash equivalents $ 693.4 $ 135.5 Restricted cash 20.0 86.0 Accounts receivable, net 2,412.4 1,201.2 Inventories 5,798.7 635.4 Prepaid expenses and other current assets 733.6 197.4 Total current assets 9,658.1 2,255.5 Non-current assets: Investments 174.0 50.8 Property, plant and equipment (“PP&E”), net 6,596.3 828.1 Goodwill 12,962.4 4,147.8 Other intangible assets, net 40,890.3 9,173.3 Deferred tax asset 129.6 121.0 Other non-current assets 309.8 33.3 Total assets 70,720.5 16,609.8 LIABILITIES AND EQUITY Current liabilities: Accounts payable and accrued expenses 3,728.1 2,050.6 Short term borrowings 2,715.2 1,511.5 Other current liabilities 411.5 144.0 Total current liabilities 6,854.8 3,706.1 Non-current liabilities: Long term borrowings 21,312.1 69.9 Deferred tax liability 10,053.8 2,205.9 Other non-current liabilities 2,736.8 798.8 Total liabilities 40,957.5 6,780.7 Equity: Common stock of 5p par value; 1,000 shares authorized; and 906.9 shares issued and outstanding (2015: 1,000 shares authorized; and 601.1 shares issued and outstanding) 81.0 58.9 Additional paid-in capital 24,473.2 4,486.3 Treasury stock: 9.1 shares (2015:9.7 shares) (302.3) (320.6) Accumulated other comprehensive loss (385.8) (183.8) Retained earnings 5,896.9 5,788.3 Total equity 29,763.0 9,829.1 Total liabilities and equity $ 70,720.5 $ 16,609.8 Unaudited US GAAP Consolidated Statements of Income (in millions) 3 months ended June 30, 6 months ended June 30, 2016 2015 2016 2015 Revenues: Product sales $ 2,322.1 $ 1,476.2 $ 3,949.4 $ 2,899.4 Royalties & other revenues 107.0 81.4 189.0 146.6 Total revenues 2,429.1 1,557.6 4,138.4 3,046.0 Costs and expenses: Cost of sales 778.1 228.0 1,026.7 455.8 Research and development 294.8 775.9 511.9 969.6 Selling, general and administrative(1) 675.3 496.0 1,150.2 914.3 Integration and acquisition costs 363.0 (212.4) 454.1 (136.7) Amortization of acquired intangible assets 213.0 131.3 347.6 219.6 Reorganization costs 11.0 13.3 14.3 28.5 Gain on sale of product rights (2.3) (7.1) (6.5) (12.3) Total operating expenses 2,332.9 1,425.0 3,498.3 2,438.8 Operating income from continuing operations 96.2 132.6 640.1 607.2 Interest income 1.6 0.6 2.6 2.6 Interest expense (87.2) (11.3) (131.9) (20.9) Other income/(expense), net 6.0 (2.0) (2.5) 2.3 Total other expense, net (79.6) (12.7) (131.8) (16.0) Income from continuing operations before income taxes and equity in (losses)/earnings of equity method investees 16.6 119.9 508.3 591.2 Income tax benefit/(charge) 70.9 44.1 (11.2) (13.3) Equity in (losses)/earnings of equity method investees, net of taxes (0.9) 0.1 (1.0) (0.9) Income from continuing operations, net of taxes 86.6 164.1 496.1 577.0 Loss from discontinued operations, net of taxes (248.7) (4.5) (239.2) (7.0) Net (loss)/income $ (162.1) $ 159.6 $ 256.9 $ 570.0 (1) Reported SG&A for periods prior to June 30, 2016 have been recast to exclude amortization of acquired intangible assets, which is now presented as a separate line item. (2) Non GAAP EBITDA as a percentage of product sales, excluding royalties and other revenues, and cost of contract manufacturing revenues. Reconciliation of US GAAP product sales to Non GAAP Gross Margin: 3 months ended June 30, 6 months ended June 30, 2016 2015 2016 2015 US GAAP Product Sales $ 2,322.1 $ 1,476.2 $ 3,949.4 $ 2,899.4 (Deduct)/add back: Cost of sales (US GAAP) (778.1) (228.0) (1,026.7) (455.8) Cost of contract manufacturing revenue 17.2 – 17.2 – Amortization of inventory fair value step-up 280.7 5.1 293.6 16.3 Costs of employee retention awards following AbbVie’s terminated offer – 2.8 – 5.5 Depreciation 22.4 13.1 30.7 24.8 Non GAAP Gross Margin $ 1,864.4 $ 1,269.2 $ 3,264.3 $ 2,490.2 Non GAAP Gross Margin % (1) 80.3% 86.0% 82.7% 85.9% (1) Non GAAP Gross Margin as a percentage of product sales. Non GAAP reconciliation for the three months and six months ended June 30, 2016 and 2015 (in millions except per ADS amounts) Reconciliation of US GAAP diluted earnings per ADS to Non GAAP diluted earnings per ADS: 3 months ended June 30, 6 months ended June 30, 2016 2015 2016 2015 US GAAP diluted earnings per ADS $ (0.71) $ 0.81 $ 1.20 $ 2.88 Amortization and asset impairments 0.72 2.79 1.22 3.07 Acquisition and integration costs 2.25 (1.08) 2.94 (0.71) Divestments, reorganizations and discontinued operations 1.12 0.02 1.17 0.07 Legal and litigation costs – 0.01 0.05 0.01 Other Non GAAP adjustments – 0.08 – 0.15 Non GAAP diluted earnings per ADS $ 3.38 $ 2.63 $ 6.58 $ 5.47 Reconciliation of US GAAP net cash provided by operating activities to Non GAAP cash generation: 3 months ended June 30, 6 months ended June 30, 2016 2015 2016 2015 Net cash provided by operating activities $ 590.9 $ 452.3 $ 980.4 $ 1,013.9 Tax and interest payments, net 262.3 53.0 365.1 7.2 Non GAAP cash generation $ 853.2 $ 505.3 $ 1,345.5 $ 1,021.1 Reconciliation of US GAAP net cash provided by operating activities to Non GAAP free cash flow: 3 months ended June 30, 6 months ended June 30, 2016 2015 2016 2015 Net cash provided by operating activities $ 590.9 $ 452.3 $ 980.4 $ 1,013.9 Capital expenditure (127.1) (20.5) (178.8) (39.8) Non GAAP free cash flow $ 463.8 $ 431.8 $ 801.6 $ 974.1 Non GAAP net debt comprises: June 30, 2016 December 31, 2015 Cash and cash equivalents $ 693.4 $ 135.5 Long term borrowings (21,312.1) (69.9) Short term borrowings (2,715.2) (1,511.5) Other debt (343.6) (13.4) Non GAAP net debt $ (23,677.5) $ (1,459.3) Reconciliation of full year 2016 US GAAP diluted earnings per ADS Outlook to Non GAAP diluted earnings per ADS Outlook: Full Year 2016 Outlook Min Max US GAAP diluted earnings per ADS $ (0.40) – $ 0.00 Amortization and asset impairments 3.07 Acquisition and integration costs 8.89 Divestments, reorganizations and discontinued operations 1.07 Legal and litigation costs 0.07 Non GAAP diluted earnings per ADS $ 12.70 – $ 13.10 NOTES TO EDITORS Stephen Williams, Deputy Company Secretary (responsible for arranging the release of this announcement). Inside Information This announcement contains inside information.

For the original version including any supplementary images or video, visit http://finance.yahoo.com/news/shire-delivers-strong-q2-2016-110000340.html

The fluid seeps in between layers of the retina and causes them to separate. There can be partial or complete loss of vision. Researchers are studying new treatments for diabetic retinopathy, including medications that may help prevent abnormal blood vessels from forming in the eye. But as it progresses, diabetic retinopathy usually causes vision loss that in many cases cannot be reversed. Retinopathy is a “silent” disease of the back of the eye – it has no symptoms during its early stage.  Laser surgery may be performed in your ophthalmologist’s office or in an outpatient clinic. http://dylanhernandezfocus.jcchristiancounseling.com/2016/08/06/due-to-their-perfect-blend-of-ingredients-the-range-of-food-is-rich-in-antioxidants-amino-acids-proteins-vitamins-and-minerals/This process can pinpoint areas that may be threatening to bleed. Diabetic retinopathy can cause vision loss in two ways: Macular enema is a condition where your retinal blood vessels develop tiny leaks. A diagnosis of retinopathy and its cause can be delayed or missed because symptoms develop gradually in some forms of retinopathy. Doppler optical coherence tomography.

Leave a Reply

Your email address will not be published. Required fields are marked *